This page is also available in:
Français
Are You Struggling With Obesity, or Being Overweight and Also Suffer from Chronic Kidney Disease?
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Would you like to take part?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling with obesity, and whether it will be made widely available to all Canadians trying to manage obesity and CKD. Study volunteers are an important part of moving medical care forward.
You may qualify to participate in this study if you:
- Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²).
- Have either no T2D with an HbA1c <6.5%, or have T2D with an HbA1c
- 10.5%, and treated with diet and exercise only with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin.
- Are on stable treatment, for at least 90 days before screening.
- Have been diagnosed with chronic kidney disease (CKD).
You may not qualify to participate if you:
- Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.
- Have used in 90 days before the screening any of the following: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting of U500 Insulins
- Have a prior or planned surgical treatment for obesity
- Have Type 1 Diabetes (T1D)
- Have acute or chronic hepatitis
- Have a history of malignant disease within 5 years before screening.
There are other eligibility requirements that the study doctor will review. Only the study doctor can finally determine whether you are eligible to participate in the study or not.
